Lilly’s Orforglipron Bests Farxiga In Type 2 Diabetes Head-to-Head

Two further Phase III readouts boost the oral GLP-1 ’s claims to be a future ‘foundational’ medicine in type 2 diabetes. (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Clinical Trials

More from R&D